Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies

ABSTRACT: Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies

PROVIDER: PRJNA1103171 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28771038_1.fastq.gz	Fastqsanger.gz
	SRR28771038_2.fastq.gz	Fastqsanger.gz
	SRR28771039_1.fastq.gz	Fastqsanger.gz
	SRR28771039_2.fastq.gz	Fastqsanger.gz
	SRR28771040_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies

Project description:Targeting cell surface molecules using radioligand and antibody–based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)––a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival. To understand how lineage markers vary across the evolution of lineage plasticity in prostate cancer, we applied single cell analyses to 21 human prostate tumor biopsies and two genetically engineered mouse models, together with tissue microarray analysis (TMA) on 131 tumor samples. Not only did we observe a higher degree of phenotypic heterogeneity in castrate–resistant PRAD and NEPC than previously anticipated, but also found that the expression of molecules targeted therapeutically, namely PSMA, STEAP1, STEAP2, TROP2, CEACAM5, and DLL3, varied within a subset of gene–regulatory networks (GRNs). We also noted that NEPC and small cell lung cancer (SCLC) subtypes shared a set of GRNs, indicative of conserved biologic pathways that may be exploited therapeutically across tumor types. While this extreme level of transcriptional heterogeneity, particularly in cell surface marker expression, may mitigate the durability of clinical responses to novel antigen–directed therapies, its delineation may yield signatures for patient selection in clinical trials, potentially across distinct cancer types.

2024-05-20 | GSE264573 | GEO

Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies.

Project description:Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)--a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival. To understand how lineage markers vary across the evolution of lineage plasticity in prostate cancer, we applied single cell analyses to 21 human prostate tumor biopsies and two genetically engineered mouse models, together with tissue microarray analysis (TMA) on 131 tumor samples. Not only did we observe a higher degree of phenotypic heterogeneity in castrate-resistant PRAD and NEPC than previously anticipated, but also found that the expression of molecules targeted therapeutically, namely PSMA, STEAP1, STEAP2, TROP2, CEACAM5, and DLL3, varied within a subset of gene-regulatory networks (GRNs). We also noted that NEPC and small cell lung cancer (SCLC) subtypes shared a set of GRNs, indicative of conserved biologic pathways that may be exploited therapeutically across tumor types. While this extreme level of transcriptional heterogeneity, particularly in cell surface marker expression, may mitigate the durability of clinical responses to novel antigen-directed therapies, its delineation may yield signatures for patient selection in clinical trials, potentially across distinct cancer types.

| S-EPMC11030323 | biostudies-literature

Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.

Project description:Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)-a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival. To understand how lineage markers vary across the evolution of lineage plasticity in prostate cancer, we applied single-cell analyses to 21 human prostate tumor biopsies and two genetically engineered mouse models, together with tissue microarray analysis on 131 tumor samples. Not only did we observe a higher degree of phenotypic heterogeneity in castrate-resistant PRAD and NEPC than previously anticipated but also found that the expression of molecules targeted therapeutically, namely PSMA, STEAP1, STEAP2, TROP2, CEACAM5, and DLL3, varied within a subset of gene-regulatory networks (GRNs). We also noted that NEPC and small cell lung cancer subtypes shared a set of GRNs, indicative of conserved biologic pathways that may be exploited therapeutically across tumor types. While this extreme level of transcriptional heterogeneity, particularly in cell surface marker expression, may mitigate the durability of clinical responses to current and future antigen-directed therapies, its delineation may yield signatures for patient selection in clinical trials, potentially across distinct cancer types.

| S-EPMC11252802 | biostudies-literature

Molecular signatures of maturing dendritic cells: implications for testing the quality dendritic cell therapies

Project description:Molecular signatures of maturing dendritic cells: implications for testing the quality dendritic cell therapies

| PRJNA437469 | ENA

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell malignancies

Project description:IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell malignancies

| PRJNA937281 | ENA

The target antigen determines the mechanism of acquired resistance to T cell based therapies

Project description:The target antigen determines the mechanism of acquired resistance to T cell based therapies

| PRJNA866375 | ENA

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

| PRJNA975812 | ENA

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

| PRJNA976061 | ENA

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

| PRJNA975578 | ENA

Synthetic dual-costimulation for TCR and TCR-like targeted cell therapies

Project description:Synthetic dual-costimulation for TCR and TCR-like targeted cell therapies

| PRJNA925223 | ENA